Global Monoclonal Antibodies Market Value to Increase by Almost $ 55 Billion During 2020-2024 | Advent of Low-priced Biosimilar Monoclonal Antibodies to Foster Growth | Technavio
The monoclonal antibodies market is poised to grow by USD 54.55 billion during 2020-2024, progressing at a CAGR of over 7% during the forecast period.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005045/en/
Technavio has announced its latest market research report titled Global Monoclonal Antibodies Market 2020-2024 (Graphic: Business Wire)
For a More Detailed Analysis, Get a Free Sample Report Delivered Instantly
The report on the monoclonal antibodies market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the advent of low-priced biosimilar monoclonal antibodies.
The monoclonal antibodies market analysis includes the application, type, and geography landscape. This study identifies the strong R&D pipeline as one of the prime reasons driving the monoclonal antibodies market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The monoclonal antibodies market covers the following areas:
Monoclonal Antibodies Market Sizing
Monoclonal Antibodies Market Forecast
Monoclonal Antibodies Market Analysis
Develop Smart Strategies for Your Business: Get a Free Sample Report Now!
Companies Mentioned
AbbVie Inc.
AstraZeneca Plc
Bristol-Myers Squibb Co.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi
Related Reports on Health Care Include:
Global Cancer Monoclonal Antibodies Market - Global cancer monoclonal antibodies market is segmented by type (naked monoclonal antibodies and conjugated and bi-specific monoclonal antibodies), MoA (immune system suppressors, kill or inhibit malignant cells, angiogenesis inhibitors, radiation therapy to cancer cells, and radiation chemotherapy to cancer cells), and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report
Global Biosimilar Monoclonal Antibodies (mAbs) Market - Global biosimilar monoclonal antibodies market is segmented by application (cancer and non-cancer) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report
Key Topics Covered:
Executive Summary
Market Landscape
Market ecosystem
Market characteristics
Value chain analysis
Market Sizing
Market definition
Market segment analysis
Market size 2019
Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
Five forces summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
Market Segmentation by Application
Market segments
Comparison by Application
Oncology - Market size and forecast 2019-2024
Autoimmune disorders - Market size and forecast 2019-2024
Infectious diseases - Market size and forecast 2019-2024
Other applications - Market size and forecast 2019-2024
Market opportunity by Application
Market Segmentation by Type
Segmentation by type of monoclonal antibodies
Customer Landscape
Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2019-2024
Europe - Market size and forecast 2019-2024
Asia - Market size and forecast 2019-2024
ROW - Market size and forecast 2019-2024
Key leading countries
Market opportunity by geography
Market drivers
Market challenges
Market trends
Vendor Landscape
Competitive Scenario
Vendor Landscape
Landscape disruption
Vendor Analysis
Vendors covered
Market positioning of vendors
AbbVie Inc.
AstraZeneca Plc
Bristol-Myers Squibb Co.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi
Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio’s in-depth research has direct and indirect COVID-19 impacted market research reports.
Subscribe to World-Class Market Intelligence and gain instant access to 17,000+ market research reports and connect with expert analysts
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005045/en/
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/